{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:46Z","timestamp":1760122126244},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.berh.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T12:53:25Z","timestamp":1321620805000},"page":"375-388","source":"Crossref","is-referenced-by-count":18,"title":["Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-\u03b1) era"],"prefix":"10.1016","volume":"25","author":[{"given":"Francesca","family":"Nacci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1286-4579(00)01282-X","article-title":"The divergent role of tumor necrosis factor receptors in infectious diseases","volume":"2","author":"Schl\u00fcter","year":"2000","journal-title":"Microbes and Infection"},{"issue":"9","key":"10.1016\/j.berh.2011.06.001_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infectious Diseases"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.bor.0000127594.92432.7c","article-title":"Infectious complications of treatment with biologic agents","volume":"16","author":"Hamilton","year":"2004","journal-title":"Current Opinion in Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2011.06.001_bib6","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety","volume":"63","author":"Hyrich","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cyto.2004.12.012","article-title":"Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy","volume":"30","author":"Popa","year":"2005","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.berh.2011.06.001_bib8","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib9","first-page":"10","article-title":"Disease modifying antirheumatic drugs: longterm safety issues","volume":"62","author":"Capell","year":"2001","journal-title":"Journal of Rheumatology Supplement"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl. 9","key":"10.1016\/j.berh.2011.06.001_bib11","article-title":"A higher rate of serious infections in patients treated with TNF alpha blocking agents","volume":"54","author":"Kievit","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl. 3","key":"10.1016\/j.berh.2011.06.001_bib12","first-page":"435","article-title":"Analysis of severe adverse events in patients with rheumatoid arthritis under the treatment with biologics; report from the registry of Japanese rheumatoid arthritis patients for long-term safety","volume":"68","author":"Komano","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcli.2010.11.032","article-title":"Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry","author":"P\u00e9rez-Sola","year":"2011","journal-title":"Medicina Clinica (Barcelona)"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib14","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Annals of Rheumatic Diseases"},{"issue":"11","key":"10.1016\/j.berh.2011.06.001_bib16","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","article-title":"Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety","volume":"9","author":"Alonso-Ruiz","year":"2008","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"12","key":"10.1016\/j.berh.2011.06.001_bib18","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2011.06.001_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.berh.2011.06.001_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.berh.2011.06.001_bib22","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rhematoid arthritis. Anti tumor necrosis factor trials in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.berh.2011.06.001_bib24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and sign and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib25","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomization, controlled trial","volume":"50","author":"St Claire","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patient with rheumatoid arthritis: double-blind randomized controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2011.06.001_bib29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/ard.2005.043299","article-title":"Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study","volume":"65","author":"van Riel","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib30","first-page":"238","article-title":"Etanercept Stusy 301 Investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2011.06.001_bib31","first-page":"2563","article-title":"Adalimumab, a fully anti tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2011.06.001_bib32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti rheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Annals of Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.06.001_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long-term efficacy and safety of Adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study","volume":"65","author":"Weinblatt","year":"2005","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib35","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib37","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar2859","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Research and Therapy"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.2010.143586","article-title":"Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial","volume":"70","author":"Strand","year":"2011","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib40","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2011.06.001_bib42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.27348","article-title":"Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study","volume":"62","author":"Kremer","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib43","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Annals of Rheumatic Diseases"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib44","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib45","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib46","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib47","series-title":"Safety update on TNF- a antagonists: infliximab and etanercept","year":"2001"},{"issue":"11\u201312","key":"10.1016\/j.berh.2011.06.001_bib48","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2298\/MPNS1012811R","article-title":"Tuberculosis in the 21st century\u2013challenges, endeavours and recommendations to doctors","volume":"63","author":"Risti\u0107","year":"2010","journal-title":"Medicinski Pregled"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0966-842X(98)01216-5","article-title":"Mechanisms of latency in Mycobacterium tuberculosis","volume":"6","author":"Parrish","year":"1998","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.berh.2011.06.001_bib50","unstructured":"World Health Organization, WHO Report 2008. Global tuberculosis control: surveillance, planning, financing, www.who.int\/tb\/pubblications\/global_report\/2008\/pdf\/fullreport.pdf."},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/eci.11.6","article-title":"The risk of tuberculosis in patients treated with TNF antagonists","volume":"7","author":"Salgado","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"issue":"20","key":"10.1016\/j.berh.2011.06.001_bib52","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"RR-17","key":"10.1016\/j.berh.2011.06.001_bib53","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","author":"Jensen","year":"2005","journal-title":"Morbidity and Mortality Weekly Report Recommendations and Reports"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib55","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubac","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib56","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Annals of Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.06.001_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2010.25.1.1","article-title":"Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis","volume":"25","author":"Storage","year":"2010","journal-title":"Korean Journal of Internal Medicine"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib58","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib59","first-page":"526","article-title":"Mycobacteria tuberculosis peritonitis associated with etanercept therapy","volume":"21","author":"Manadan","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib60","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib61","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl. 3","key":"10.1016\/j.berh.2011.06.001_bib63","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib64","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.11134","article-title":"Tuberculosis in the cytokine era: what rheumatologists need to know","volume":"48","author":"Hamilton","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.06.001_bib65","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib66","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib67","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1297-319X(02)00387-1","article-title":"Recommendations about the prevention and management of tuberculosis I patients taking infliximab","volume":"69","author":"Salmon","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2011.06.001_bib68","unstructured":"http:\/\/agmed.sante.gouv.fr\/htm\/10\/tnf\/reco.pdf"},{"key":"10.1016\/j.berh.2011.06.001_bib69","first-page":"77","article-title":"Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update","volume":"33","author":"Fonseca","year":"2008","journal-title":"Acta Reumatol\u00f3gica Portuguesa"},{"issue":"Suppl. 3","key":"10.1016\/j.berh.2011.06.001_bib70","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2006.061937","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases","volume":"65","author":"Furst","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.berh.2011.06.001_bib71","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib72","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.berh.2011.06.001_bib73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"Tuberculine skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clinical Infectious Disease"},{"issue":"12","key":"10.1016\/j.berh.2011.06.001_bib74","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infectious Diseases"},{"issue":"9","key":"10.1016\/j.berh.2011.06.001_bib75","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Le\u00f3n","year":"2005","journal-title":"Annals of Rheumatic Diseases"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.berh.2011.06.001_bib77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/ajrccm.163.4.ed0201c","article-title":"Diagnosing latent tuberculosis infection: the 100-year upgrade","volume":"163","author":"Barnes","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"RR-15","key":"10.1016\/j.berh.2011.06.001_bib78","first-page":"49","article-title":"Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"Morbidity and Mortality Weekly Report Recommendations and Report"},{"issue":"9235","key":"10.1016\/j.berh.2011.06.001_bib79","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(00)02742-2","article-title":"Specific immune-based diagnosis of tuberculosis","volume":"356","author":"Andersen","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2011.06.001_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200402-179OC","article-title":"Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens","volume":"170","author":"Mori","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"22","key":"10.1016\/j.berh.2011.06.001_bib81","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1001\/jama.293.22.2756","article-title":"Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country","volume":"293","author":"Kang","year":"2005","journal-title":"Journal of the American Medical Association"},{"issue":"12","key":"10.1016\/j.berh.2011.06.001_bib82","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","article-title":"Comparison of in\u00a0vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy","volume":"66","author":"Sellam","year":"2007","journal-title":"Annals of Rheumatic Diseases"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib83","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.00107608","article-title":"QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases","volume":"33","author":"Bartalesi","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1016\/j.berh.2011.06.001_bib84","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2011.06.001_bib85","unstructured":"National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, www.nice.org.uk\/CG33."},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.06.001_bib86","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2010.146852","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010","volume":"70","author":"Furst","year":"2011","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.06.001_bib87","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.berh.2011.06.001_bib88","first-page":"733","article-title":"Update: fatal and severe liver injurie associated with rifapin and pyrazinamide for latent tuberculosis infection, and revision in the American Thoracic Society\/CDC recommendations-USA 2001","volume":"50","year":"2001","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.berh.2011.06.001_bib89","first-page":"289","article-title":"Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection \u2013 New York and Georgia, 2000","volume":"50","year":"2001","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.berh.2011.06.001_bib90","first-page":"265","article-title":"Impact of screening for latent TB prior to initiating anti TNF therapy in North America and Europe","volume":"64","author":"Perez","year":"2005","journal-title":"Quality and Safety in Health Care"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/RHU.0b013e3181bf93cd","article-title":"Systemic listeriosis with adalimumab therapy","volume":"15","author":"Murphy","year":"2009","journal-title":"Journal of Clinical Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib92","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.rmed.2005.09.020","article-title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area","volume":"100","author":"Jain","year":"2006","journal-title":"Respiratory Medicine"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib93","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib94","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Marchesoni A.Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib95","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.berh.2006.08.010","article-title":"Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy","volume":"20","author":"Strangfeld","year":"2006","journal-title":"Best Practice and Research Clinical Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib96","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib97","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Annals of Rheumatic Diseases"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib98","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2011.06.001_bib99","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection","volume":"63","author":"Calabrese","year":"2004","journal-title":"Annals of Rheumatic Diseases"},{"issue":"11","key":"10.1016\/j.berh.2011.06.001_bib100","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.berh.2011.06.001_bib101","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.22783","article-title":"Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis","volume":"57","author":"Balandraud","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib102","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar2708","article-title":"Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies","volume":"11","author":"Miceli-Richard","year":"2009","journal-title":"Arthritis Research and Therapy"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2249.1998.00469.x","article-title":"Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection","volume":"111","author":"Kallinowski","year":"1998","journal-title":"Clinical and Experimental Immunology"},{"issue":"12","key":"10.1016\/j.berh.2011.06.001_bib104","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1023\/A:1018804426724","article-title":"Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection","volume":"42","author":"Nelson","year":"1997","journal-title":"Digestive Diseases and Sciences"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib105","first-page":"1372","article-title":"Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases","volume":"9","author":"Monsalve-De Castillo","year":"2002","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib106","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/clinids\/18.2.194","article-title":"Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis","volume":"18","author":"Torre","year":"1994","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1016\/j.berh.2011.06.001_bib107","first-page":"748","article-title":"Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection","volume":"91","author":"Fang","year":"1996","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.berh.2011.06.001_bib108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.1840140108","article-title":"Increased tumor necrosis factor-alpha receptor number in chronic hepatitis B virus infection","volume":"14","author":"Lau","year":"1991","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.berh.2011.06.001_bib109","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Annals of Rheumatic Diseases"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1016\/j.berh.2011.06.001_bib111","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.autrev.2008.05.002","article-title":"Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases","volume":"8","author":"Cavazzana","year":"2008","journal-title":"Autoimmunity Reviews"},{"issue":"3","key":"10.1016\/j.berh.2011.06.001_bib112","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/039463201002300335","article-title":"Etanercept therapy in patients with psoriasis and concomitant HCV infection","volume":"23","author":"Garavaglia","year":"2010","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"10","key":"10.1016\/j.berh.2011.06.001_bib113","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib114","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10067-008-0896-y","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports","volume":"27","author":"Oniankitan","year":"2008","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2011.06.001_bib115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn\u2019s disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"9","key":"10.1016\/j.berh.2011.06.001_bib116","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","article-title":"Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action","volume":"29","author":"Carroll","year":"2010","journal-title":"Clinical Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2011.06.001_bib117","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still\u2019s disease","volume":"30","author":"Michel","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2011.06.001_bib118","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.06.001_bib119","first-page":"S3","article-title":"EASL Jury. EASL International consensus conference on hepatitis B. 13\u201314 September, 2002 Geneva, Switzerland. Consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"Journal of Hepatology"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T19:54:32Z","timestamp":1560974072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694211000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521694211000635"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2011.06.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}